Insulin lispro

Insulin lispro

Clinical data
ATC code	A10AB04 (WHO)
Identifiers
CAS Number	133107-64-9
PubChem CID	16132438
DrugBank	BTD00065
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C257H389N65O77S6
Molar mass	5813.63 g/mol

WikiDoc Resources for Insulin lispro
Articles
Most recent articles on Insulin lispro Most cited articles on Insulin lispro Review articles on Insulin lispro Articles on Insulin lispro in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Insulin lispro Images of Insulin lispro Photos of Insulin lispro Podcasts & MP3s on Insulin lispro Videos on Insulin lispro
Evidence Based Medicine
Cochrane Collaboration on Insulin lispro Bandolier on Insulin lispro TRIP on Insulin lispro
Clinical Trials
Ongoing Trials on Insulin lispro at Clinical Trials.gov Trial results on Insulin lispro Clinical Trials on Insulin lispro at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Insulin lispro NICE Guidance on Insulin lispro NHS PRODIGY Guidance FDA on Insulin lispro CDC on Insulin lispro
Books
Books on Insulin lispro
News
Insulin lispro in the news Be alerted to news on Insulin lispro News trends on Insulin lispro
Commentary
Blogs on Insulin lispro
Definitions
Definitions of Insulin lispro
Patient Resources / Community
Patient resources on Insulin lispro Discussion groups on Insulin lispro Patient Handouts on Insulin lispro Directions to Hospitals Treating Insulin lispro Risk calculators and risk factors for Insulin lispro
Healthcare Provider Resources
Symptoms of Insulin lispro Causes & Risk Factors for Insulin lispro Diagnostic studies for Insulin lispro Treatment of Insulin lispro
Continuing Medical Education (CME)
CME Programs on Insulin lispro
International
Insulin lispro en Espanol Insulin lispro en Francais
Business
Insulin lispro in the Marketplace Patents on Insulin lispro
Experimental / Informatics
List of terms related to Insulin lispro

For patient information, click here

Insulin lispro (marked by Lilly as "Humalog®") is a fast acting insulin analogue; it was the first insulin analogue.

It was engineered through recombinant DNA technology so that the penultimate lysine and proline residues on the C-terminal end of the B-chain were reversed. This modification did not alter receptor binding, but blocked the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be available for postprandial (after meal) injections.